Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Approval for Suboxone (buprenorphine and naloxone) Sublingual Film C-III

Richmond, VA (31st August 2010) – Reckitt Benckiser Pharmaceuticals Inc. today announces that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) to manufacture and market Suboxone… (Source: Drugs.com – New Drug Approvals)

Drug Treatment as HIV Prevention: Expanding Treatment Options

Abstract  Research conducted during the first 20 years of the AIDS epidemic provided a solid foundation of data supporting methadone
treatment as HIV prevention. Drug users in methadone treatment were consistently found to reduce the frequency of drug use,
risk behaviors, and infections. These data have been consistent over time and across cultural settings and have been used
to promote the expansion of drug treatment as a prevention intervention. More recently, data have emerged suggesting the prevention
potential of medication-assisted treatments other than methadone (buprenorphine/naloxone and naltrexone). Still, with a few
notable exceptions, global drug treatment coverage for opiate injectors remains remarkably low and only a few treatment interventions
for stimul…

Drug Treatment as HIV Prevention: Expanding Treatment Options

Abstract  Research conducted during the first 20 years of the AIDS epidemic provided a solid foundation of data supporting methadone
treatment as HIV prevention. Drug users in methadone treatment were consistently found to reduce the frequency of drug use,
risk behaviors, and infections. These data have been consistent over time and across cultural settings and have been used
to promote the expansion of drug treatment as a prevention intervention. More recently, data have emerged suggesting the prevention
potential of medication-assisted treatments other than methadone (buprenorphine/naloxone and naltrexone). Still, with a few
notable exceptions, global drug treatment coverage for opiate injectors remains remarkably low and only a few treatment interventions
for stimul…

Drug Treatment as HIV Prevention: Expanding Treatment Options

Abstract  Research conducted during the first 20 years of the AIDS epidemic provided a solid foundation of data supporting methadone
treatment as HIV prevention. Drug users in methadone treatment were consistently found to reduce the frequency of drug use,
risk behaviors, and infections. These data have been consistent over time and across cultural settings and have been used
to promote the expansion of drug treatment as a prevention intervention. More recently, data have emerged suggesting the prevention
potential of medication-assisted treatments other than methadone (buprenorphine/naloxone and naltrexone). Still, with a few
notable exceptions, global drug treatment coverage for opiate injectors remains remarkably low and only a few treatment interventions
for stimul…

Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects

Abstract: Previous reports have demonstrated greater antinociception following administration of a buprenorphine/naloxone combination compared to buprenorphine alone among healthy volunteers. The aim of the current investigation was to determine whether buprenorphine antinociception could be enhanced with the addition of ultra-low dose naltrexone, using a range of dose ratios. A repeated-measures, double-blind, cross-over trial was undertaken with 10 healthy participants. The effects of each buprenorphine:naltrexone ratio (100:1, 133:1, 166:1, and 200:1) on cold pressor tolerance time and respiration were compared to the effects of buprenorphine only. The 166:1 ratio was associated with significantly greater tolerance time to cold pressor pain than buprenorphine alone. Minimal respiratory …